Oxyntomodulin: actions and role in diabetes

Jens J. Holst; Nicolai J. Wewer Albrechtsen; Maria Buur Nordskov Gabe; Mette Marie Rosenkilde

doi:10.1016/j.peptides.2017.09.018

Oxyntomodulin: actions and role in diabetes

Jens J. Holst, Nicolai J. Wewer Albrechtsen, Maria Buur Nordskov Gabe, Mette Marie Rosenkilde

Endocrinology and Metabolism

27 Citations (Scopus)

Abstract

Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.

Original language	English
Journal	Peptides
Volume	100
Pages (from-to)	48-53
Number of pages	6
ISSN	0196-9781
DOIs	https://doi.org/10.1016/j.peptides.2017.09.018
Publication status	Published - 2018

Keywords

Journal Article
Review
Diabetes
Oxyntomodulin
Proglucagon

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.peptides.2017.09.018

Cite this

@article{d93172b12e7740fcbcda6cb16f68399b,

title = "Oxyntomodulin: actions and role in diabetes",

abstract = "Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.",

keywords = "Journal Article, Review, Diabetes, Oxyntomodulin, Proglucagon",

author = "Holst, {Jens J.} and Albrechtsen, {Nicolai J. Wewer} and Gabe, {Maria Buur Nordskov} and Rosenkilde, {Mette Marie}",

year = "2018",

doi = "10.1016/j.peptides.2017.09.018",

language = "English",

volume = "100",

pages = "48--53",

journal = "Peptides",

issn = "0196-9781",

publisher = "Elsevier",

}

TY - JOUR

T1 - Oxyntomodulin

T2 - actions and role in diabetes

AU - Holst, Jens J.

AU - Albrechtsen, Nicolai J. Wewer

AU - Gabe, Maria Buur Nordskov

AU - Rosenkilde, Mette Marie

PY - 2018

Y1 - 2018

N2 - Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.

AB - Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33-69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.

KW - Journal Article

KW - Review

KW - Diabetes

KW - Oxyntomodulin

KW - Proglucagon

U2 - 10.1016/j.peptides.2017.09.018

DO - 10.1016/j.peptides.2017.09.018

M3 - Review

C2 - 29412831

SN - 0196-9781

VL - 100

SP - 48

EP - 53

JO - Peptides

JF - Peptides

ER -

Oxyntomodulin: actions and role in diabetes

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this